Ironwood presented data from the Phase II STARS Nutrition program at UEG Week

Ironwood Pharmaceuticals presented positive final data from the company’s Phase II STARS Nutrition program during United European Gastroenterology, or UEG, Week. This multicenter study of nine patients was designed to evaluate the safety, pharmacokinetics, and efficacy of apraglutide, an investigational next-generation, long-acting synthetic GLP-2 analog, on intestinal absorption in adult patients who have Short Bowel Syndrome with Intestinal Failure, or SBS-IF, and Colon-in-Continuity, or CIC. Positive interim results from this study were first announced in October 2022. The data from STARS Nutrition were featured at UEG Week during a late-breaker oral presentation titled “The Long-Acting GLP-2 Analog Apraglutide Provides Clinical Benefit For Patients With Short Bowel Syndrome With Intestinal Failure And Colon In Continuity At 52 Weeks.” The presentation highlighted that apraglutide had an acceptable safety profile, which was the primary study objective, and that apraglutide improved intestinal absorption as indicated by 50% parenteral support (PS) volume and energy content decrease, resulting in one or more days off PS. PS reduction was observed as early as week four and was maintained until the end of the study. 78% of patients gained one or more days off PS with all patients achieving clinical response.